Notice of Extraordinary General Meeting Radiopharm Theranostics Limited ACN 647 877 889 1 Notice of Extraordinary General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice is given that the Extraordinary General Meeting of...
Notice of Extraordinary General Meeting and Proxy Form
Filed with ASX · · 39 pages · English
Release
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Share Purchase Plan - Now Open
- Update - Proposed issue of securities - RAD
- Application for quotation of securities - RAD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Change in substantial holding
Later from Radiopharm Theranostics
- RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- Ceasing to be a substantial holder
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics